Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

- PMLiVE

Pfizer drug gets speedy FDA review for rare heart failure complication

Tafamidis chalked up a comprehensive win in its phase III trials programme

- PMLiVE

More encouraging data for Spark and Pfizer’s potential haemophilia B cure

Pfizer set to commence phase III trials

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

- PMLiVE

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

Roche Basel Switzerland

Another IO knockback as Tecentriq combo fails phase III trial

The bulk of CRC patients with MSS currently look set to be excluded from cancer immunotherapy

Roche Basel Switzerland

Roche eyes September FDA verdict for triple NSCLC therapy

Roche hot on the heels of Merck in first-line non-small cell lung cancer market

- PMLiVE

Pfizer’s flat sales focus investor attention on M&A

But CEO Ian Reed insists that there is no need for a large-scale acquisition

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links